PPARγ在前列腺癌中的研究进展  

Research Progress of PPARγ in Prostate Cancer

作　　者：常耀 王子成 赵德龙 郭安东 丁森泰 

机构地区：[1]山东第一医科大学附属省立医院,山东 济南 [2]山东第一医科大学,山东 济南

出　　处：《临床医学进展》2023年第2期1962-1967,共6页Advances in Clinical Medicine

摘　　要：过氧化氢酶体增殖物激活受体(peroxisome proliferator-activated receptors, PPARS)是一种核受体超家族中的配体激活转录因子,该受体共有三种亚型,即PPARα、PPARβ/δ、PPARγ。他们在机体内调节脂质激活基因转录、参与脂质代谢、降低炎症反应、细胞增殖和分化。其中PPAR-γ配体具有抗增殖和促分化作用,在前列腺癌中具有抗肿瘤作用。现综述PPARγ在前列腺癌中的研究进展,旨在讨论PPARγ参与前列腺癌发生发展的机制及其在前列腺癌诊断、治疗的潜在价值。Peroxisome proliferator-activated receptors (PPARS) is a ligand-activated transcription factor in the nuclear receptor superfamily, which has three subtypes, namely PPARα, PPARβ/δ and PPARγ. They regulate lipid-activated gene transcription, participate in lipid metabolism, and reduce inflamma-tory response, cell proliferation and differentiation in the body. Among them, the PPAR-γ ligand has anti-proliferation and differentiation-promoting effects, and has anti-tumor effects in prostate can-cer. This article reviews the research progress of PPARγ in prostate cancer, aiming to discuss the mechanism of PPARγ involved in the development of prostate cancer and its potential value in the diagnosis and treatment of prostate cancer.

关 键 词：PPARΓ 前列腺癌 PPARΓ激动剂 

分 类 号：R73[医药卫生—肿瘤]